Amneal Pharmaceuticals, Inc. AMRX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $197.66M-29.9% | $282.03M+40.1% | $201.25M+181% | $71.54M+20.9% | $59.19M-46.5% | ||
| -$44.01M-526% | $10.34M-86.7% | $77.61M— | —— | —— | ||
| $641.62M+5.8% | $606.3M-1.3% | $614.5M+0.9% | $608.97M+1.3% | $601.43M-1.8% | ||
| $1.8B-5.9% | $1.91B+4.0% | $1.84B+16.0% | $1.58B+4.9% | $1.51B-4.9% | ||
| $444.61M+0.4% | $442.95M+1.8% | $434.99M-1.2% | $440.33M+3.1% | $427.23M+0.5% | ||
| $593.8M-0.3% | $595.47M-0.1% | $595.95M-0.2% | $597.41M0.0% | $597.5M0.0% | ||
| $534.87M-5.1% | $563.5M-4.2% | $587.94M-9.5% | $649.55M-5.7% | $689.14M-5.9% | ||
| $3.54B-3.8% | $3.68B+2.2% | $3.6B+5.2% | $3.42B+1.7% | $3.37B-3.9% | ||
| $6.2M-8.3% | $6.76M-6.1% | $7.2M-76.9% | $31.18M-1.9% | $31.79M-85.8% | ||
| $728.05M-17.4% | $881.63M+2.3% | $862.11M-22.1% | $1.11B+2.9% | $1.08B-4.8% | ||
| $2.57B0.0% | $2.57B-0.1% | $2.57B+19.6% | $2.15B-0.4% | $2.15B-0.4% | ||
| $2.77B-0.7% | $2.79B+0.4% | $2.78B+17.7% | $2.36B+0.6% | $2.35B-2.8% | ||
| —— | —— | —— | —— | —— | ||
| -$472.75M+11.6% | -$535.01M+6.2% | -$570.08M+0.4% | -$572.45M+3.8% | -$594.87M+2.0% | ||
| -$45.41M+35.9% | -$70.79M+35.3% | -$109.46M+2.4% | -$112.12M+14.8% | -$131.67M-20.5% | ||
| $3.54B-3.8% | $3.68B+2.2% | $3.6B+5.2% | $3.42B+1.7% | $3.37B-3.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Amneal Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 2.47 — current assets exceed current liabilities.
- Where does Amneal Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.